Yevgeniy Brailovsky, DO
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1356604607
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,069 of the $25,093 with a category attached, or 64.0%. 26 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 33.8% of the total. 2025 is the largest year on record at $18,589, more than ten times the $893 reported in 2019.
Across 199 payments — averaging $126.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$8K
- Pfizer$6K
- Abbott$3K
- Bridgebio Pharma, Inc.$3K
- AstraZeneca$1K
- Impulse Dynamics (USA) Inc.$1K
- plus $2K from 20 others
Across 25 payments — averaging $12,566 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$220K
- AstraZeneca$51K
- Boston Scientific$28K
- Eidos Therapeutics, Inc.$15K
What the payments were for
- Consulting fees$16,06964%
- Speaking & faculty fees$2741%
- Travel & lodging$1,6497%
- Food & beverage$6,89927%
- Education$2021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 14 | $8,469 |
| Pfizer | 33 | $6,196 |
| Abbott | 61 | $2,856 |
| Bridgebio Pharma, Inc. | 3 | $2,721 |
| AstraZeneca | 10 | $1,387 |
| Impulse Dynamics (USA) Inc. | 21 | $1,099 |
| Medtronic(2 entities) | 3 | $716 |
| Novartis | 19 | $292 |
| Edwards Lifesciences | 2 | $212 |
| Boehringer Ingelheim | 7 | $158 |
| Amgen | 5 | $125 |
| Novo Nordisk | 1 | $114 |
| Daxor Corporation | 2 | $114 |
| One Lambda, Inc. | 1 | $101 |
| United Therapeutics Corporation | 1 | $100 |
| Abiomed | 2 | $70 |
| Actelion Pharmaceuticals US, Inc. | 2 | $61 |
| Scpharmaceuticals Inc. | 2 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Endotronix, Inc. | 1 | $50 |
| Cvrx, Inc. | 1 | $41 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Livanova USA, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Merck | 1 | $15 |
| Nuwellis, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$5,674
- Attruby$2,690
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$934
- OPTIMIZER$931
- HeartMate 3 Left Ventricular Dev$288
- THORATEC HEARTMATE 3$151
- Ensite Cardiac Mapping System$142
- Ozempic$114
- WAINUA$112
How this compares
$25,093 in reported general payments places this provider in the 75th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 457 | $10,646,712 |
| VyndaqelTafamidis Meglumine | 42 | $927,795 |
| LivtencityMaribavir | 18 | $434,874 |
| EntrestoSacubitril/Valsartan | 236 | $249,182 |
| EliquisApixaban | 117 | $114,158 |
| JardianceEmpagliflozin | 124 | $111,325 |
| FarxigaDapagliflozin Propanediol | 87 | $72,181 |
| XareltoRivaroxaban | 40 | $33,579 |
| Praluent PenAlirocumab | 22 | $16,135 |
| VemlidyTenofovir Alafenamide | 11 | $14,024 |
| Sirolimus | 14 | $5,493 |
| Tacrolimus | 23 | $3,766 |
| Mycophenolate Mofetil | 15 | $3,689 |
| Amiodarone Hcl | 59 | $2,889 |
| Atorvastatin Calcium | 173 | $2,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $6,196 | $11,688,666616 claims |
| NovartisEntresto | $292 | $249,182236 claims |
| Boehringer IngelheimJardiance | $158 | $111,325124 claims |
| AstraZenecaFarxiga | $1,387 | $72,18187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.